Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables - Accured: 2019-2024

Historic Receivables - Accured for Spyre Therapeutics (SYRE) over the last 6 years, with Dec 2024 value amounting to $3.4 million.

  • Spyre Therapeutics' Receivables - Accured rose 111.76% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 111.76%. This contributed to the annual value of $3.4 million for FY2024, which is 277.78% up from last year.
  • Per Spyre Therapeutics' latest filing, its Receivables - Accured stood at $3.4 million for FY2024, which was up 277.78% from $900,000 recorded in FY2023.
  • Spyre Therapeutics' 5-year Receivables - Accured high stood at $3.4 million for FY2024, and its period low was $100,000 during FY2021.
  • Over the past 3 years, Spyre Therapeutics' median Receivables - Accured value was $900,000 (recorded in 2023), while the average stood at $1.5 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Receivables - Accured tumbled by 50.00% in 2021, and later spiked by 800.00% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Receivables - Accured (Yearly) stood at $200,000 in 2020, then plummeted by 50.00% to $100,000 in 2021, then remained steady at $100,000 in 2022, then surged by 800.00% to $900,000 in 2023, then surged by 277.78% to $3.4 million in 2024.